๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
Cambridge, London, Oxford, Salford
2024-11-25
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Genmab
Phase 3
191
Glasgow, London, Manchester, Nottingham, Plymouth
2024-11-25
Recruiting
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
NCT06651281Crohn Disease, Colitis, Ulcerative
Merck Sharp & Dohme LLC
Phase 3
1,380
London, Prescot
2024-11-25
Active, closed
RCT on the Performance and Safety of LightForceยฎ Therapy Lasers on Knee Osteoarthritis Pain Reduction (SPARK)
NCT06654739Osteoarthritis of Knee
DJO UK Ltd
Not applicable
64
Leeds
2024-11-23
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich
2024-11-21
Active, closed
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
50
Cardiff, Leeds, Liverpool, London, Southampton
2024-11-21
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
67
Torquay, Truro
2024-11-21
Recruiting
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQยฎ
NCT06498128Insomnia
Idorsia Pharmaceuticals Ltd.
Observational
785
London
2024-11-21
Active, closed
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
NCT06660667Neovascular Age-related Macular Degeneration
Sanofi
Phase 1/2
66
London, Liverpool
2024-11-21
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
Daiichi Sankyo
Phase 3
700
Birmingham, Harrow, London, Maidstone, Manchester, Oxford, Torquay
2024-11-19
By invitation
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
NCT06435312Generalized Myasthenia Gravis
UCB Biopharma SRL
Phase 3
8
Glasgow, London
2024-11-19
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
Eli Lilly and Company
Phase 3
125
Barnsley, Bristol, Cambridge, Dundee, Harrow, Hull, Liverpool
2024-11-18
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Recruiting
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939Obesity, Overweight
Eli Lilly and Company
Phase 3
150
Barnsley, Dundee, Hull
2024-11-18
Active, closed
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
NCT06681181Colitis, Ulcerative
GlaxoSmithKline
Phase 1
48
Cambridge
2024-11-18
Recruiting
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378Chronic Granulomatous Disease (CGD)
Ensoma
Observational
60
London
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Endeavor Biomedicines, Inc.
Phase 2
213
Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry
2024-11-15
Recruiting
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587Solid Tumor
Genentech, Inc.
Phase 1
410
Edinburgh, London, Manchester, Sutton
2024-11-14
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Aberdeen, Bristol, Camberley, Derby, Edgbaston, Birmingham, Exeter, Glasgow, Hull
2024-11-12
Active, closed
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B
GlaxoSmithKline
Phase 2
283
London, Middlesbrough
2024-11-11
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 3
367
Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London
2024-11-11
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155Systemic Sclerosis (SSc)
argenx
Phase 2
81
Leeds, London, Luton
2024-11-11
Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naรฏve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499Metastatic Castration-Resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1
106
Sutton, Birmingham, Glasgow
2024-11-11
Active, closed
A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
NCT06713135Duchenne Muscular Dystrophy
Santhera Pharmaceuticals
Phase 4
80
Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle
2024-11-10
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
52
Sutton
2024-11-08
Recruiting
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
NCT06659341Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer
Phase 1
104
Manchester, Sutton
2024-11-08
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
Sanofi
Phase 2
556
Ruislip, Corby, Nottingham, Oxford, Barnsley, Bradford, London
2024-11-07
Recruiting
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
NCT05582993Von Willebrand Disease (VWD)
Takeda
Phase 3
24
London, Oxford
2024-11-06
Recruiting
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrioยฎ in Fabry Patients
NCT06663358Fabry Disease
Chiesi Farmaceutici S.p.A.
Observational
100
Edgbaston, Salford, London
2024-11-06
Active, closed
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
NCT06647407Meningococcal Immunization, Healthy Volunteers
Sanofi Pasteur, a Sanofi Company
Phase 1/2
750
Exeter, London, Southampton
2024-11-05
Recruiting
The Use of Smart Devices in Capturing Digital Biomarkers in Eating Disorders
NCT06544226Eating Disorders
Univa Health
Observational
130
Liverpool
2024-11-01
Recruiting
First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System
NCT06423690Lung Cancer
Snipe Medical
Not applicable
15
London
2024-11-01
Recruiting
Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer
NCT06649123Colorectal Cancer, Adenoma Colon Polyp
Origin Sciences
Observational
6,600
Telford
2024-11-01
Recruiting
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
Verve Therapeutics, Inc.
Phase 1
36
Liverpool, London, Manchester
2024-10-30
Recruiting
A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
NCT06453512Atopic Eczema
Dermal Laboratories Ltd
Not applicable
65
Nottingham
2024-10-30
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Regeneron Pharmaceuticals
Phase 3
975
Liverpool, York, Bristol, London, Newcastle upon Tyne
2024-10-30
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Janssen Research & Development, LLC
Phase 3
196
Sheffield, Stoke-on-Trent
2024-10-29
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
Pulmovant, Inc.
Phase 2
135
Cambridge, London, Clydebank
2024-10-29
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
Novartis Pharmaceuticals
Phase 2
96
Sheffield
2024-10-29
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Sheffield, Cambridge, London
2024-10-24
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth
2024-10-24
Recruiting
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
NCT06343805Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
London, Oxford
2024-10-23
Active, closed
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
NCT06660563Lymphoma, Non-Hodgkin
Janssen Research & Development, LLC
Phase 1
19
Leicester
2024-10-22
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 3
900
Blackburn, Chelmsford, Derby, Glasgow, Metropolitan Borough of Wirral
2024-10-22
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer
Phase 3
600
Blackburn, Westcliff-on-Sea, Edinburgh, Glasgow, London, Metropolitan Borough of Wirral, Swansea
2024-10-21
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
argenx
Phase 3
69
Birmingham, Bradford, Coventry, Glasgow, Leicester, London, Truro
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Recruiting
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860Diabetic Peripheral Neuropathic Pain
Vertex Pharmaceuticals Incorporated
Phase 2
300
Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield
2024-10-18
Recruiting
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Oxford
2024-10-17
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals
Phase 2
251
Sheffield, Farnborough, London, Stoke-on-Trent
2024-10-17
By invitation
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
NCT06559176Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Prime Medicine, Inc.
Phase 1/2
12
London
2024-10-17
Active, closed
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371Asthma
Amgen
Phase 1
21
Cambridge, London, Manchester
2024-10-16
Recruiting
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
NCT06055959Generalized Myasthenia Gravis
UCB Biopharma SRL
Phase 2/3
8
Glasgow, London
2024-10-16
Active, closed
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462Eosinophilic Esophagitis (EoE)
Uniquity One (UNI)
Phase 2
184
Whitechapel, London
2024-10-16
Recruiting
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFฮฑ Inadequate Response
NCT06641089Arthritis, Psoriatic
MoonLake Immunotherapeutics AG
Phase 3
600
Westcliff-on-Sea, Barnet, Leeds, Wolverhampton
2024-10-15
Recruiting
Study of ATX-01 in Participants With DM1
NCT06300307Myotonic Dystrophy 1
ARTHEx Biotech S.L.
Phase 1/2
56
London
2024-10-15
Active, closed
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Mirum Pharmaceuticals, Inc.
Phase 3
90
London
2024-10-14
Active, closed
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
Merck Sharp & Dohme LLC
Phase 2
66
Bodelwyddan, London, Oxford, Manchester
2024-10-14
Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168Primary Biliary Cholangitis
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449Huntington's Disease
Alnylam Pharmaceuticals
Phase 1
66
Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth
2024-10-14
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Aberdeen, Ashton in Makerfield, Bristol, Camberley, Edgbaston, Birmingham, Edgware, Enfield, London, Exeter
2024-10-14
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
Boehringer Ingelheim
Phase 2
588
Dundee, London, Manchester
2024-10-11
Active, closed
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Chronic Graft-versus-host-disease
Incyte Corporation
Phase 2
130
Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2024-10-11
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
Ipsen
Phase 2
670
Exeter, Hull, Liverpool, London
2024-10-10
Active, closed
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
NCT06646289X-Linked Retinitis Pigmentosa
Janssen Research & Development, LLC
Phase 2
24
London
2024-10-10
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
Incyte Corporation
Phase 3
346
Dudley, Ipswich, Liverpool, London, Poole, Redhill
2024-10-10
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Basingstoke, Bristol, London
2024-10-09
Active, closed
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789TGCT
SynOx Therapeutics Limited
Phase 3
128
Leeds, London
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
Gilead Sciences
Phase 3
609
Birmingham, Brighton, London
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
Gilead Sciences
Phase 3
600
Brighton, Great Maze Pond, London
2024-10-08
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Exeter, Dundee, Larbert, Glasgow, London, Leicester, Manchester, Metropolitan Borough of Wirral
2024-10-07
Active, closed
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
NCT06513312Pre-Exposure Prophylaxis of HIV Infection
Gilead Sciences
Phase 2
268
Birmingham, Brighton, Liverpool, London, Manchester
2024-10-07
Active, closed
Development of a New Patient Reported Outcome Measure (PROM) to Assess Patient's Emotional Wellbeing, and Perceptions of Total Knee Replacement Surgery for the Treatment of Knee Arthritis
NCT06585267Complete Questionnaires Following TKR Surgery
Invibio Ltd
Observational
167
Leeds
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Birmingham, Cambridge, Glasgow, Leicester, London, Manchester, Middlesbrough
2024-10-04
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
Cardiff, Plymouth, Wakefield
2024-10-03
Recruiting
Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
NCT06569602Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Observational
500
Oxford
2024-10-01
Active, closed
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
NCT06506955Advanced/Metastatic Cancer
Taiho Oncology, Inc.
Phase 2/3
15
London
2024-10-01
Recruiting
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
NCT06617897Acquired Fibrinogen Deficiency
CSL Behring
Phase 3
90
Basingstoke
2024-10-01
Recruiting
TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety
NCT06364488Depression, Depression, Postpartum, Anxiety in Pregnancy, Anxiety
BlueSkeye AI
Not applicable
125
Nottingham
2024-10-01
Active, closed
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent ฮฒ-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals
Phase 2
19
London
2024-09-30
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
Belfast, Liverpool, London, Southampton
2024-09-30
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
Sanofi
Phase 2
900
Cambridge, Glasgow, Bradford, Chertsey, London
2024-09-30
Recruiting
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT05663515Pancreatic Cancer
AstraZeneca
Observational
24,000
Edinburgh, London
2024-09-30
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142Neoplasms
GlaxoSmithKline
Phase 1
845
Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne
2024-09-30
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Birmingham, London
2024-09-30
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
GlaxoSmithKline
Phase 2
393
Bristol, Cambridge, Glasgow Strathclyde, Leeds West Yorkshire, Liverpool, London, Middlesbrough, Plymouth
2024-09-27
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
Stemline Therapeutics, Inc.
Phase 3
4,220
Truro, Brighton, London, Cheltenham, Northwood, Blackpool, Preston, Livingston
2024-09-27
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
GAP Innovations, PBC
Observational
1,200
Motherwell, London
2024-09-26
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
Longboard Pharmaceuticals
Phase 3
96
Newcastle upon Tyne, Glasgow, London
2024-09-25
Recruiting
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
NCT06512454Alpha1-Antitrypsin Deficiency
Takeda
Observational
500
Birmingham
2024-09-25
Recruiting
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
Merus B.V.
Phase 3
700
Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton
2024-09-25
Recruiting
Trial of THEO-260 in Ovarian Cancer Patients
NCT06618235Ovarian Cancer
Theolytics Limited
Phase 1/2
44
Glasgow, London, Oxford
2024-09-24
Active, closed
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
NCT06504446Refractory or Unexplained Chronic Cough
Nocion Therapeutics
Phase 2
455
Belfast, Bristol, Cottingham, London, Wythenshawe, Nottingham, North Shields
2024-09-24
Active, closed
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants โ‰ฅ18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis
ModernaTX, Inc.
Phase 3
37,864
High Wycombe, Runcorn, Truro, London, Orpington, Blackpool, Rochdale, Salford
2024-09-24
Active, closed
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT06436742Congenital Myasthenic Syndrome, CMS
argenx
Phase 1
15
Belfast, Oxford
2024-09-24
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals
Phase 3
500
Glasgow, Leicester, Liverpool, London
2024-09-24
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
338
Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay
2024-09-23
Active, closed
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027Parkinson Disease
Cerevance
Phase 3
330
Newcastle upon Tyne, Bury, London, Plymouth
2024-09-20
Rows per page Showing 1001–1100 of 2847
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=11

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.